سعر كميسيلاز 2.5 مجم 10 أقراص 2022

Kemicilaz cilazapril 2.5 mg film-coated tablets, pack of 10, by Chemipharm (Egypt).

• Canada: mild to moderate essential hypertension (normally when a diuretic or beta-blocker was ineffective or not tolerated).Population: AdultsHealth Canada Drug Product Database
• Canada: adjunctive therapy of chronic heart failure with digitalis and/or diuretics.Population: AdultsHealth Canada Drug Product Database

• Common: dizziness, headache, cough, fatigue, nausea. Uncommon: angioedema, hypotension, among others.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• Ireland: hypersensitivity to cilazapril, other ACE inhibitors or excipients; history of angioedema with previous ACE inhibitor therapy; hereditary or idiopathic angioedema; second and third trimesters; aliskiren in diabetes or GFR <60 mL/min/1.73 m2.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland
• Canada: hypersensitivity; hereditary/idiopathic or ACE-inhibitor angioedema; anuria; ascites; pregnancy, planned pregnancy or no adequate contraception; nursing women; aliskiren in diabetes or GFR <60 mL/min/1.73 m2.International label, equivalent formulation · Health Canada Drug Product Database

• Symptomatic hypotension (especially after the first dose and in volume/salt-depleted or heart-failure patients); angioedema, which may occur at any time (higher risk with mTOR or DPP-4 inhibitors); anaphylactoid reactions during high-flux dialysis, LDL apheresis or desensitisation.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland
• Renal impairment and renal artery stenosis, hyperkalaemia, neutropenia/agranulocytosis, hepatic effects (cholestatic jaundice), hypoglycaemia in diabetics, hypotension during surgery/anaesthesia, aortic stenosis/hypertrophic cardiomyopathy; dual RAAS blockade not recommended; tablets contain lactose.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• LithiumReversible increases in serum lithium and toxicity; monitor lithium levels.Health Products Regulatory Authority (HPRA), Ireland
• Potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutesRisk of hyperkalaemia.Health Products Regulatory Authority (HPRA), Ireland
• NSAIDsReduced antihypertensive effect and increased risk of worsening renal function and hyperkalaemia.Health Products Regulatory Authority (HPRA), Ireland

• Canada: contraindicated in pregnant women, women planning pregnancy and women of child-bearing potential not using adequate contraception.International label, equivalent formulation · Health Canada Drug Product Database
• Ireland: not recommended during breastfeeding; alternatives with better established safety are preferred.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland
• Canada: contraindicated in nursing women.International label, equivalent formulation · Health Canada Drug Product Database

• Cilazapril: Prodrug converted to cilazaprilat, a specific long-acting ACE inhibitor that suppresses the renin-angiotensin-aldosterone system, reducing angiotensin II formation (Irish SmPC).